Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.

Wang, Zhenhua; Sun, Ruixiaotong; Sheng, Yanan; Qu, Shuli; Dong, Lu; Wu, Bin

Wang, Zhenhua; Sun, Ruixiaotong; Sheng, Yanan; Qu, Shuli; Dong, Lu; Wu, Bin.

Afiliación

Wang Z; Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Sun R; Real-World Solutions, IQVIA, Beijing, China.
Sheng Y; Medical Affairs, Takeda (China) International Trading Company, Beijing, China.
Qu S; Real-World Solutions, IQVIA, Beijing, China.
Dong L; Medical Affairs, Takeda (China) International Trading Company, Beijing, China.
Wu B; Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Ann Transl Med ; 10(8): 480, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35571388

Palabras clave

China; cost-effectiveness; proton pump inhibitors (PPIs); reflux esophagitis (RE); vonoprazan (VPZ)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Ann Transl Med Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google